Abstract:Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic target to improve the effectiveness of immune therapies. Prior research has focused largely on the two major ectonucleotidases, ectonucleoside triphosphate diphosphohydrolase 1/cluster of differentiation (CD)39 and ecto-5'-nucleotidase/CD73, which catalyze the breakdown of extracellular ATP into adenosine, and on the subsequent activation of different subtypes of adenosine receptors with mixed findings of antitumor and protumor effects. New findings, needed for more effective therapeutic approaches, require consideration of redundant pathways controlling intratumoral adenosine levels, including the alternative NAD-inactivating pathway through the CD38-ectonucleotide pyrophosphatase phosphodiesterase (ENPP)1-CD73 axis, the counteracting ATP-regenerating ectoenzymatic pathway, and cellular adenosine uptake and its phosphorylation by adenosine kinase. This review provides a holistic view of extracellular and intracellular adenosine metabolism as an integrated complex network and summarizes recent data on the underlying mechanisms through which adenosine and its precursors ATP and ADP control cancer immunosurveillance, tumor angiogenesis, lymphangiogenesis, cancer-associated thrombosis, blood flow, and tumor perfusion. Special attention is given to differences and commonalities in the purinome of different cancers, heterogeneity of the tumor microenvironment, subcellular compartmentalization of the adenosine system, and novel roles of purine-converting enzymes as targets for cancer therapy. Significance Statement The discovery of the role of adenosine as immune checkpoint regulator in cancer has led to the development of novel therapeutic strategies targeting extracellular adenosine metabolism and signaling in multiple clinical trials and preclinical models. Here we identify major gaps in knowledge that need to be filled to improve the therapeutic gain from agents targeting key components of the adenosine metabolic network and, on this basis, provide a holistic view of the cancer purinome as a complex and integrated network.

Targeting adenosine for cancer immunotherapy

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy

Targeting immunosuppressive adenosine in cancer

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy

Targeting Hypoxia‐Adenosinergic Signaling to Enable Effective Anti‐Tumor Responses by Reprogramming the Immunosuppressive Tumor Microenvironment

CD39/CD73/A2AR pathway and cancer immunotherapy

The adenosine pathway in immuno-oncology

Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain

Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer

The Immune Regulatory Role of Adenosine in the Tumor Microenvironment

Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors

Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.

The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies

Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Nanoparticles targeting the adenosine pathway for cancer immunotherapy

The Adenosinergic Pathway in Non-Small Cell Lung Cancer

Adenosine Signaling: Next Checkpoint for Gastric Cancer Immunotherapy?